Rifabutin-vonoprazan conjugate 1

製品番号: HY-181038: Data Sheet 取扱説明書
FAQs
Technical Support

Rifabutin-vonoprazan conjugate 1 is an orally active acid-responsive bifunctional molecule. Rifabutin-vonoprazan conjugate 1 exhibits anti-Helicobacter pylori activity (MIC ≤ 0.125 μg/mL) and acid-suppressive effects (acid inhibition rate > 85% at a dose of 2 mg/kg). Rifabutin-vonoprazan conjugate 1 also demonstrates anti-ulcer activity. Rifabutin-vonoprazan conjugate 1 can be used in research related to Helicobacter pylori infection and gastric ulcer.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

Rifabutin-vonoprazan conjugate 1 構造式

容量		在庫状況
MOQ		Minimum order quantity
50 mg		お問い合わせ
100 mg		お問い合わせ
250 mg		お問い合わせ
Other size		お問い合わせ

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

おすすめ

•関連小分子:

•関連タンパク質:

生物活性
純度とドキュメンテーション
参考文献
カスタマーレビュー

製品説明

体外実験

Rifabutin-vonoprazan conjugate 1 (Compound 10) (0.125-64 μg/mL; 48 h) inhibits H. pylori ATCC 700392, demonstrating activity comparable to rifabutin (HY-17025)^[1].
Rifabutin-vonoprazan conjugate 1 (1 μM; 50 min) exhibitS a 9.66% inhibition rate against porcine gastric H⁺/K⁺-ATPase^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

Rifabutin-vonoprazan conjugate 1 (2 mg/kg; oral gavage; single dose) inhibits gastric acid secretion in both the basal and stimulated models in SD rats^[1].
Rifabutin-vonoprazan conjugate 1 (0.3-3 mg/kg; oral gavage; single dose) exhibits dose-dependent anti-ulcer activity in mice ^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Sprague-Dawley (SD) (male, 250-280 g)^[1]
Dosage:	2 mg/kg
Administration:	i.g.; single dose
Result:	Achieved 34.24% inhibition rate in basal gastric acid secretion model. Achieved 64.97% inhibition rate in 2-Deoxy-D-glucose (HY-13966)-stimulated gastric acid secretion model. Achieved 87.17% inhibition rate in Histamine (HY-B1204)-stimulated gastric acid secretion model.

Animal Model:	Mice treated water-immersion restraint stress^[1]
Dosage:	0.3, 0.75, 1.5, and 3 mg/kg
Administration:	i.g.; single dose
Result:	Induced dose-dependent reduction in ulcer area between 0.3 and 1.5 mg/kg. Showed most pronounced effect at 1.5 mg/kg, with antiulcer efficacy comparable to Vonoprazan (HY-100007) at 3 mg/kg. Exacerbated ulcers at 3 mg/kg.

分子量

1972.51

分子式

C₁₀₄H₁₃₉FN₁₀O₂₁SSi₂

SMILES

CC(C)[Si](C(C)C)(OCCCCCC1=CN(CCCCCCO[Si](C(C)C)(OC2=CC=C(COC(N(C)CC3=CN(S(=O)(C4=CC=CN=C4)=O)C(C5=CC=CC=C5F)=C3)=O)C=C2)C(C)C)N=N1)OC6=CC=C(COC(N7C8(CCN(CC(C)C)CC8)N=C(C7=C(NC(/C(C)=C\C=C\[C@H](C)[C@@H]([C@@H](C)[C@@H](O)[C@@H](C)[C@@H]([C@H](C)[C@@H](OC)/C=C/O9)OC(C)=O)O)=O)C%10=O)C%11=C%10C(O)=C(C)C(O[C@@]%129C)=C%11C%12=O)=O)C=C6

輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Please store the product under the recommended conditions in the Certificate of Analysis.

純度とドキュメンテーション

取扱説明書 (2659 KB)

参考文献

[1]. Wen R, et al. Design, Synthesis, and Biological Evaluation of Acid-Responsive Bifunctional Molecules with Dual Anti-Helicobacter pylori and Acid Suppression Activities. J Med Chem. 2026 Jan 22;69(2):1342-1357. [Content Brief]